NASDAQ: ALMRAlamar Biosciences Inc Stock
$30.80+0.23 (+0.75%)
Updated Sep 4, 2026
ALMR Price
$30.80
Fair Value Price
$2.71
Market Cap
$2.14B
52 Week Low
$18.85
52 Week High
$38.54
P/E
N/A
P/B
6.83x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.25
Operating Cash Flow
N/A
Beta
0.67
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ALMR Overview
Alamar Biosciences operates as a commercial-stage proteomics firm, specializing in the highly sensitive, simultaneous identification of various proteins for both scientific research and prospective medical applications. Their integrated platform brings together proprietary instruments, specialized consumables, and unique software, forming a comprehensive, end-to-end solution. This system is designed for accurately quantifying multiple proteins, particularly those present in low concentrations, across a wide array of research and potential clinical uses.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ALMR's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important ALMR news, forecast changes, insider trades & much more!
ALMR News
Overview
Due Diligence Score
–
Industry Average (30)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ALMR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ALMR ($30.80) is overvalued by 1,035.64% relative to our estimate of its Fair Value price of $2.71 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ALMR ($30.80) is not significantly undervalued (1,035.64%) relative to our estimate of its Fair Value price of $2.71 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ALMR is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more ALMR due diligence checks available for Premium users.
Valuation
ALMR fair value
Fair Value of ALMR stock based on Discounted Cash Flow (DCF)
Price
$30.80
Fair Value
$2.71
Overvalued by
1,035.64%
ALMR ($30.80) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ALMR ($30.80) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ALMR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.83x
Industry
3.23x
ALMR is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ALMR's financial health
Profit margin
Revenue
$29.4M
Net Income
-$13.2M
Profit Margin
-44.9%
Assets to liabilities
Assets
$391.0M
Liabilities
$78.1M
Debt to equity
0.25
ALMR's short-term assets ($331.38M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ALMR's short-term assets ($331.38M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ALMR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$11.3M
Investing
-$120.8M
Financing
$201.8M
ALMR vs Medical Device Stocks
Alamar Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.